MedTrace Logo

Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

NCT05736523 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2025-03-07

No results posted yet for this study

Summary

This is a non-randomized experimental biomarker study evaluating ctDNA levels in patients with stage IIB/C and stage IIIB/C/D melanoma skin cancer pre and post-surgery

Study participants will complete a ctDNA test within 4 weeks of their planned surgical resection of their melanoma. Within 4 weeks post-surgery another ctDNA test will be completed. During these time points stool samples and diet questionnaires will be collected for biospecimen banking.

Conditions

Sponsors & Collaborators

  • Intermountain Medical Center

    collaborator OTHER

  • Natera, Inc.

    collaborator INDUSTRY

  • University of Utah

    lead OTHER

Principal Investigators

  • John Hyngstrom, MD · Huntsman Cancer Institute/ University of Utah

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-23
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05736523 on ClinicalTrials.gov